FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug

• The FDA is intensifying its scrutiny of Eli Lilly's experimental Alzheimer's drug, conducting deeper assessments of its safety and effectiveness.
• This decision comes after concerns were raised by an advisory panel regarding the drug's efficacy and potential side effects.
• The FDA aims to gather more comprehensive data to determine the medication's potential risks and benefits for Alzheimer's patients.
• The scrutiny underscores the challenges in developing effective treatments for Alzheimer's disease, a condition with limited therapeutic options.
• Eli Lilly's drug, donanemab, is among several experimental treatments aiming to address the underlying causes of Alzheimer's, but its efficacy and safety profile remain under evaluation.